A Global Microbial Signature for Colorectal Cancer

Single studies can disagree, especially in microbiome research where diet, geography, and lab methods vary. This 2019 analysis tackled that problem head-on by combining many studies into one rigorous picture.

What the researchers did

The team gathered stool sequencing data from eight separate colorectal cancer studies across multiple continents, totaling 768 patients alongside healthy comparisons. They carefully accounted for confounding factors such as body weight, age, and medication use. They then used machine learning, deliberately testing the patterns on data the models had never seen, to find bacteria reliably tied to cancer rather than to any single study’s quirks.

What they found

• A consistent core of 29 bacterial species was enriched in colorectal cancer stool, including Fusobacterium nucleatum and several other mouth-associated microbes.
• The signature was reproducible across Europe, Asia, and North America — a strong sign it reflects real biology, not local artifacts.
• The cancer-associated gut communities showed a metabolic shift: more genes for breaking down protein and mucus, and fewer for fermenting dietary fiber into beneficial short-chain fatty acids.

“By training on multiple studies, we improved detection accuracy and disease specificity for colorectal cancer.”

This work is among the most robust evidence that the gut microbiome carries meaningful information about gut health. It is shared here for education and is not medical advice.